Education

PhD, Newcastle University, England, 2008

Current position

Senior Lecturer and Honorary Consultant in Urology Newcastle University and Sunderland Royal Hospital, England

Publications

1. McClurg, U. L., Chit, N., Azizyan, M., Edwards, J., Nabbi, A., Riabowol, K. T., Nakjang, S., McCracken, S. R. and Robson, C. N. (2018). Molecular mechanism of the TP53-MDM2-AR-AKT signalling network regulation by USP12. Oncogene 37(34): 4679-4691. 
2. McClurg, U. L., Nabbi, A., Ricordel, C., Korolchuk, S., McCracken, S., Heer, R., Wilson, L., Butler, L. M., Irving-Hooper, B. K., Pedeux, R., Robson, C. N., Riabowol, K. T. and Binda, O. (2018). Human ex vivo prostate tissue model system identifies ING3 as an oncoprotein. Br J Cancer 118(5): 713-726.
3. McClurg, U. L., Harle, V. J., Nabbi, A., Batalha-Pereira, A., Walker, S., Coffey, K., Gaughan, L., McCracken, S. R. and Robson, C. N. (2015). Ubiquitin-specific protease 12 interacting partners Uaf-1 and WDR20 are potential therapeutic targets in prostate cancer. Oncotarget 6(35): 37724-37736. 
4. Gao, M., Patel, R., Ahmad, I., Fleming, J., Edwards, J., McCracken, S., Sahadevan, K., Seywright, M., Norman, J., Sansom, O. and Leung, H. Y. (2012). SPRY2 loss enhances ErbB trafficking and PI3K/AKT signalling to drive human and mouse prostate carcinogenesis. EMBO Mol Med 4(8): 776-790.
5. Ramsay, A. K., McCracken, S. R., Soofi, M., Fleming, J., Yu, A. X., Ahmad, I., Morland, R., Machesky, L., Nixon, C., Edwards, D. R., Nuttall, R. K., Seywright, M., Marquez, R., Keller, E. and Leung, H. Y. (2011). ERK5 signalling in prostate cancer promotes an invasive phenotype. Br J Cancer 104(4): 664-672.
6. Gaughan, L., Stockley, J., Wang, N., McCracken, S. R., Treumann, A., Armstrong, K., Shaheen, F., Watt, K., McEwan, I. J., Wang, C., Pestell, R. G. and Robson, C. N. (2011). Regulation of the androgen receptor by SET9-mediated methylation. Nucleic Acids Res 39(4): 1266-1279.